Cas:527-35-5 2,3,5,6-tetramethylphenol manufacturer & supplier

We serve Chemical Name:2,3,5,6-tetramethylphenol CAS:527-35-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

2,3,5,6-tetramethylphenol

Chemical Name:2,3,5,6-tetramethylphenol
CAS.NO:527-35-5
Synonyms:Phenol,3,5,6-tetramethyl;Phenol,tetramethyl;2,5,6-Tetramethylphenol;2,3,4,5-TETRAMETHYLPYRROLE;Durenol;Phenol,2,3,5,6-tetramethyl;2,3,5,6-tetramethyl-phenol;3-Hydroxy-1.2.4.5-tetramethyl-benzol
Molecular Formula:C10H14O
Molecular Weight:150.21800
HS Code:2907199090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:248.6ºC at 760 mmHg
Density:0.982g/cm3
Index of Refraction:1.532
PSA:20.23000
Exact Mass:150.10400
LogP:2.62580

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like Phenol,3,5,6-tetramethyl chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-Hydroxy-1.2.4.5-tetramethyl-benzol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,3,5,6-tetramethyl-phenol Use and application,3-Hydroxy-1.2.4.5-tetramethyl-benzol technical grade,usp/ep/jp grade.


Related News: Professionally produce and submit DMF files, and supplement data at any time during the patent challenge of formulation companies. 2,3,5,6-tetramethylphenol manufacturer But Sanofi’s rival CD38 antibody Sarclisa may soon be able to challenge Darzalex in the same front-line, transplant-ineligible population with the help of a more powerful backbone. 2,3,5,6-tetramethylphenol supplier But Sanofi’s rival CD38 antibody Sarclisa may soon be able to challenge Darzalex in the same front-line, transplant-ineligible population with the help of a more powerful backbone. 2,3,5,6-tetramethylphenol vendor The foundational patent, which expires in 2034, is owned by MSK and is licensed exclusively to Fate Therapeutics for all human therapeutic uses. 2,3,5,6-tetramethylphenol factory The foundational patent, which expires in 2034, is owned by MSK and is licensed exclusively to Fate Therapeutics for all human therapeutic uses.